SLC2A1 and metabolic syndrome: We also recapitulate LF can alleviate insulin resistance by inhibiting the NF-κB inflammatory pathway, activating the IRS/PI3K/Akt/Glut signaling pathway, and inhibiting the renin-angiotensin system to reduce the blood pressure, therefore improving the metabolic syndrome.